Seattle, WA, United States of America

Daniel Adriano Silva Manzano

USPTO Granted Patents = 9 

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
9 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Daniel Adriano Silva Manzano

Introduction

Daniel Adriano Silva Manzano is a prominent inventor based in Seattle, WA. He has made significant contributions to the field of biotechnology, particularly in the design of interleukin mimetics. With a total of nine patents to his name, his work has the potential to impact therapeutic approaches in immunology.

Latest Patents

Manzano's latest patents include groundbreaking designs such as "De novo design of potent and selective interleukin mimetics." This patent discloses de novo designed polypeptides that bind to the IL-2 receptor β heterodimer, IL-4 receptor α heterodimer, or IL-13 receptor α subunit. Additionally, he has developed "Split interleukin mimetics and their use," which describes conditionally active receptor agonists that, when activated, bind to the same receptors, along with methods for their application.

Career Highlights

Throughout his career, Manzano has worked with esteemed institutions such as the University of Washington and Stanford University. His innovative research has positioned him as a key figure in the development of new therapeutic strategies targeting interleukin pathways.

Collaborations

Some of his notable collaborators include David Baker and Umut Ulge. Their combined expertise has contributed to the advancement of research in the field of immunology.

Conclusion

Daniel Adriano Silva Manzano's work exemplifies the spirit of innovation in biotechnology. His patents and collaborations reflect a commitment to advancing medical science through the design of novel therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…